Levamisole for children with nephrotic syndrome: new evidence for the use of an "old" drug

Marina Vivarelli, Francesco Emma

Research output: Contribution to journalArticlepeer-review

Abstract

In the current issue of Kidney International, Sinha et al. report results of a randomized controlled trial comparing levamisole and mycophenolate mofetil for the second-line treatment of children with frequent relapses of nephrotic syndrome. This study suggests that these two agents may both be safe and effective. The present commentary addresses strengths and limitations of this important study.

Original languageEnglish
Pages (from-to)25-28
Number of pages4
JournalKidney International
Volume95
Issue number1
DOIs
Publication statusPublished - Jan 2019

Keywords

  • Child
  • Glucocorticoids
  • Humans
  • Immunosuppressive Agents
  • Levamisole
  • Mycophenolic Acid
  • Nephrotic Syndrome
  • Recurrence

Fingerprint

Dive into the research topics of 'Levamisole for children with nephrotic syndrome: new evidence for the use of an "old" drug'. Together they form a unique fingerprint.

Cite this